Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$185.10
+0.2%		$197.53
$137.03
▼
$216.90
$51.83B0.552.64 million shs860,138 shs
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$896.29
-0.7%		$1,003.32
$740.01
▼
$1,153.99
$260.97B1.292.20 million shs673,073 shs
Moderna, Inc. stock logo
MRNA
Moderna
$199.45
+5.0%		$125.46
$22.28
▼
$208.90
$79.63B1.0911.90 million shs5.55 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
0.00%-1.05%-7.28%+6.32%+25.25%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
0.00%-3.42%-12.94%-14.33%+14.34%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-4.46%+30.55%+132.29%+566.94%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$185.10
+0.2%		$197.53
$137.03
▼
$216.90
$51.83B0.552.64 million shs860,138 shs
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$896.29
-0.7%		$1,003.32
$740.01
▼
$1,153.99
$260.97B1.292.20 million shs673,073 shs
Moderna, Inc. stock logo
MRNA
Moderna
$199.45
+5.0%		$125.46
$22.28
▼
$208.90
$79.63B1.0911.90 million shs5.55 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
0.00%-1.05%-7.28%+6.32%+25.25%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
0.00%-3.42%-12.94%-14.33%+14.34%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-4.46%+30.55%+132.29%+566.94%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
2.96
Moderate Buy$226.3322.28% Upside
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.39
Hold$1,073.6019.78% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$77.83-60.98% Downside

Current Analyst Ratings Breakdown

Latest FANG, GS, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$60.00 ➝ $80.00
9/28/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$995.00 ➝ $1,007.00
9/25/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
9/25/2026
Moderna, Inc. stock logo
MRNA
Moderna
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
9/25/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$1,325.00 ➝ $1,175.00
9/23/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$1,200.00 ➝ $1,050.00
9/23/2026
Moderna, Inc. stock logo
MRNA
Moderna
Singular Research logo
Singular Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
9/22/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/18/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/17/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Stephens logo
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$255.00
9/17/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$15.03B3.45$31.16 per share5.94$150.03 per share1.23
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$125.10B2.09$64.11 per share13.98$366.15 per share2.45
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B40.96N/AN/A$22.14 per share9.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$1.66B$5.1336.0810.37N/A8.58%10.10%6.16%11/2/2026 (Estimated)
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$17.18B$64.7913.8312.320.9315.53%19.16%1.07%10/13/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)

Latest FANG, GS, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/2/2026Q3 2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$4.99N/AN/AN/A$4.55 billionN/A
10/13/2026Q3 2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$14.27N/AN/AN/A$17.12 billionN/A
8/3/2026Q2 2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$6.08$6.48+$0.40$6.65$4.89 billion$5.56 billion
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
7/14/2026Q2 2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$14.47$20.98+$6.51$20.98$16.22 billion$20.34 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$4.402.38%+21.67%85.77%7 Years
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$20.002.23%+22.87%30.87%13 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest FANG, GS, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/13/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
quarterly$5.002%9/1/20269/1/20269/29/2026
7/30/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
quarterly$1.102.21%8/13/20268/13/20268/20/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
0.25
0.47
0.45
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
3.17
0.63
0.63
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18

Institutional Ownership

CompanyInstitutional Ownership
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
90.01%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
71.21%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
0.64%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
0.55%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
1,762280.02 million278.23 millionOptionable
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
47,400291.17 million289.57 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable

Recent News About These Companies

Jim Cramer Says This Stock Could Rise Like Moderna (MRNA)
October 4 at 12:19 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/jim-cramer-says-stock-could-232006963.html
Moderna (MRNA) Soars 175% in Q3: Can The Stock Keep Running?
October 4 at 12:19 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/moderna-mrna-soars-175-q3-030725604.html
SA asks: Is Moderna's stock now a sell after the recent run-up?
October 4 at 2:18 PM  |  msn.comhttps://www.msn.com/en-us/news/other/sa-asks-is-modernas-stock-now-a-sell-after-the-recent-run-up/ar-AA2dytKH
Promising Biotech Stocks Worth Watching - October 4th
October 4 at 12:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-promising-biotech-stocks-worth-watching-october-4th-2026-10-04/
Citigroup downgrades Moderna to sell from neutral
October 3 at 11:50 PM  |  msn.comhttps://www.msn.com/en-us/news/other/citigroup-downgrades-moderna-to-sell-from-neutral/ar-AA2dvU66
Top Biotech Stocks To Add to Your Watchlist - October 3rd
October 3 at 12:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-top-biotech-stocks-to-add-to-your-watchlist-october-3rd-2026-10-03/
Top Biotech Stocks To Add to Your Watchlist - September 30th
October 3 at 5:03 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082637
Why Is Moderna (MRNA) Bringing Back A Manufacturing Leader As First COO?
October 2 at 10:46 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/why-moderna-mrna-bringing-back-220558467.html
Healthcare Stocks To Keep An Eye On - October 2nd
October 2 at 1:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-healthcare-stocks-to-keep-an-eye-on-october-2nd-2026-10-02/
Moderna (MRNA) Stock Rallies on Nasdaq-100 Inclusion News
October 2 at 12:44 PM  |  coincentral.comC
Biotech Stocks To Watch Now - October 2nd
October 2 at 12:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-biotech-stocks-to-watch-now-october-2nd-2026-10-02/
SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot
October 2 at 7:43 AM  |  stocktwits.comS
Why Is Moderna, Inc. (NASDAQ: MRNA) Stock Up 569% This Year?
October 2 at 6:34 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078286
Moderna stock rises 2% on Nasdaq 100 entry but this analyst says sell
October 2 at 6:09 AM  |  invezz.comI
Moderna loses US government license defense in Northwestern patent case
October 2 at 1:27 AM  |  reuters.comhttps://www.reuters.com/legal/government/moderna-loses-us-government-license-defense-northwestern-patent-case-2026-10-01/
Moderna slips as Citi cuts to Sell on “unjustifiable” valuation
October 2 at 1:27 AM  |  seekingalpha.comhttps://seekingalpha.com/news/4648418-moderna-stock-slips-citi-cuts-sell
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/moderna-mrna-stock-dips-while-205005439.html
Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/moderna-inc-join-nasdaq-100-000000029.html
Moderna to replace Warner Bros Discovery  on Nasdaq 100
October 1, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/moderna-join-nasdaq-100-replacing-warner-bros-discovery-2026-10-02/
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
October 1, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2999206/moderna-mrna-stock-dips-while-market-gains-key-facts?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v1-2999206
After Moderna's 'Outsized Run,' It May Be Time For This Bearish Move
October 1, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/after-modernas-outsized-run-it-may-be-time-for-this-bearish-move/ar-AA2dmyvv

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
Stacks of US currency and an official document sit on a desk in a government chamber.
3 Stocks to Buy and Hold for Higher Interest Rates
By Thomas Hughes | September 9, 2026
Autonomous military drone with AV-style logo on the nose sitting on a runway, representing AeroVironment and the defense drone industry.
AeroVironment's Record Backlog and Earnings Beat Fuel Recovery Case
By Thomas Hughes | September 10, 2026
Shopping bags sit on a polished marble floor inside an upscale retail store or shopping mall.
3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
By Nathan Reiff | September 16, 2026
Computer monitor with a red plunging chart arrow on a desk, symbolizing software stocks selloff amid AI fears.
MarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
By Thomas Hughes | September 15, 2026
Diamondback Energy stock logo

Diamondback Energy NASDAQ:FANG

$185.10 +0.39 (+0.21%)
As of 11:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Diamondback Energy, Inc., an independent oil and natural gas company, acquires, develops, explores, and exploits unconventional, onshore oil and natural gas reserves in the Permian Basin in West Texas. It focuses on the development of the Spraberry and Wolfcamp formations of the Midland basin; and the Wolfcamp and Bone Spring formations of the Delaware basin, which are part of the Permian Basin in West Texas and New Mexico. The company also owns and operates midstream infrastructure assets, in the Midland and Delaware Basins of the Permian Basin. Diamondback Energy, Inc. was founded in 2007 and is headquartered in Midland, Texas.

The Goldman Sachs Group stock logo

The Goldman Sachs Group NYSE:GS

$896.29 -6.27 (-0.69%)
As of 11:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

Moderna stock logo

Moderna NASDAQ:MRNA

$199.45 +9.44 (+4.97%)
As of 11:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas